BusinessAmaranth Medical Showcases Breadth of BRS Pipeline at TCT, Unveiling 9-mo Interim Imaging Results from 98 micron MAGNITUDE and Update on 115-micron APTITUDEBy Nasdaq OMXOct 25, 2017, 5:22 PM UTC
BusinessAmaranth Medical Initiates Trial of Sub-100-Micron MAGNITUDE Sirolimus-Eluting Bioresorbable ScaffoldBy Nasdaq OMXNov 1, 2016, 12:00 PM UTC
BusinessAmaranth Medical 9-Months Clinical and Imaging Results of the FORTITUDE Sirolimus-Eluting Bioresorbable Scaffold Presented at TCTBy Nasdaq OMXOct 31, 2016, 4:30 PM UTC
